Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Branded Legacy
Vancouver, British Columbia, Canadabrandedlegacy.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Branded Legacy, via BioLegacy, is developing a patented air-driven intranasal drug delivery device (lead: naloxone for overdose reversal). Clinical trials targeted for 2026 with market launch of the naloxone device planned for Q1 2027. Additional programs aim to use the device for vaccines and difficult-to-deliver compounds, but no published clinical results yet.[2][3][7]
- Therapeutic areas
- Infectious DiseasesNeurologyPsychiatry
- Modalities
- DeviceSmall molecule
- Industry
- Therapeutic Medical Devices
02
Partnerships
McMaster UniversityStanford University
Beyond the preview
Go deeper on Branded Legacy.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Branded Legacy.